A Phase 2 Study of Oral Difelikefalin for Moderate-to-Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)

Main Article Content

Brian S Kim
Robert Bissonnette
Kristine Nograles
Catherine Munera
Nilam Shah
Alia Jebara
Joshua Cirulli
Joana Goncalves
Mark Lebwohl


notalgia paresthetica, KOMFORT, difelikefalin, phase 2, clinical trial




1. Ellis C. Dermatol Pract Concept. 2013;3:3-6

2. Fishbane S, et al. N Engl J Med. 2020;382:222-232

3. Topf J, et al. Kidney Med. 2022;4(8):100512

4. Korsuva. Package insert. Cara Therapeutics, Inc.; 2021

5. Kapruvia. Summary of product characteristics. Vifor Fresenius Medical Care Renal Pharma France; 2022

6. Kim BS, et al. Oral difelikefalin reduces pruritus in atopic dermatitis. Presented at: the 30th European Academy of Dermatology and Venereology Congress; September 29–October 2, 2021

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>